Pyxis Oncology, Inc.
PYXS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $10 | $11 | $13 | $19 |
| Short-Term Investments | $67 | $78 | $93 | $107 |
| Receivables | $0 | $3 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $5 | $8 | $6 | $6 |
| Total Curr. Assets | $83 | $100 | $112 | $132 |
| Property Plant & Equip (Net) | $20 | $21 | $21 | $22 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $2 | $2 | $0 | $3 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $23 | $23 | $24 | $25 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $106 | $123 | $136 | $157 |
| Liabilities | – | – | – | – |
| Payables | $10 | $9 | $3 | $5 |
| Short-Term Debt | $2 | $2 | $2 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $8 | $7 | $10 | $11 |
| Total Curr. Liab. | $19 | $18 | $14 | $18 |
| LT Debt | $17 | $18 | $18 | $19 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $17 | $18 | $18 | $19 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $17 | $19 | $20 | $20 |
| Total Liabilities | $37 | $36 | $33 | $36 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$425 | -$403 | -$385 | -$364 |
| AOCI | $0 | -$0 | $0 | $0 |
| Other Equity | $494 | $491 | $488 | $484 |
| Total Equity | $69 | $88 | $103 | $121 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $106 | $123 | $136 | $157 |
| Net Debt | $9 | $9 | $7 | $1 |